Linked Life Data

21094862

Source:http://linkedlifedata.com/resource/pubmed/id/21094862

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21094862rdf:typepubmed:Citationlld:pubmed
pubmed-article:21094862lifeskim:mentionsumls-concept:C1123023lld:lifeskim
pubmed-article:21094862lifeskim:mentionsumls-concept:C0040732lld:lifeskim
pubmed-article:21094862lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:21094862lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:21094862lifeskim:mentionsumls-concept:C0026336lld:lifeskim
pubmed-article:21094862lifeskim:mentionsumls-concept:C0567416lld:lifeskim
pubmed-article:21094862lifeskim:mentionsumls-concept:C0450127lld:lifeskim
pubmed-article:21094862lifeskim:mentionsumls-concept:C0038925lld:lifeskim
pubmed-article:21094862lifeskim:mentionsumls-concept:C0600688lld:lifeskim
pubmed-article:21094862lifeskim:mentionsumls-concept:C0547040lld:lifeskim
pubmed-article:21094862lifeskim:mentionsumls-concept:C0205276lld:lifeskim
pubmed-article:21094862lifeskim:mentionsumls-concept:C1705822lld:lifeskim
pubmed-article:21094862lifeskim:mentionsumls-concept:C1524063lld:lifeskim
pubmed-article:21094862lifeskim:mentionsumls-concept:C0205349lld:lifeskim
pubmed-article:21094862lifeskim:mentionsumls-concept:C0205373lld:lifeskim
pubmed-article:21094862lifeskim:mentionsumls-concept:C1515895lld:lifeskim
pubmed-article:21094862pubmed:issue9lld:pubmed
pubmed-article:21094862pubmed:dateCreated2010-11-24lld:pubmed
pubmed-article:21094862pubmed:abstractTextThe effects of OX40-OX40 ligand (OX40L) costimulatory pathway blockade to prevent T-cell-mediated acute rejection were investigated in a rat model of allogeneic superficial inferior epigastric artery flap transplantation. An ex vivo gene transfer technique was used to modify allografts to locally deliver an immunomodulatory molecule. The flaps were separated from donors, perfused with an adenoviral vector expressing the OX40 immunoglobulin (AdOX40Ig) for 1 hour, and incubated at 37°C for 2 hours. Before transplantation, the flaps were flushed with phosphate-buffered saline solution to remove unincorporated viral particles. Recipients were randomly divided into 5 groups, and treated with topical OX40Ig gene transfer, a single low dose of rapamycin alone, or a combination of agents. Graft survival was assessed using histopathologic classification of skin rejection. All animals in the untreated group (n = 9) or the group treated with adenovirus expressing green fluorescence protein (n = 9) developed grade 3 clinical rejection by postoperative day 7. No significant difference was observed in graft survival between the locally treated AdOX40Ig groups (mean [SD], 8.1 [0.7] days) and the untreated groups (7.7 [1.2] days) could be observed (P > .05, t test). Graft survival in the locally treated AdOX40Ig groups was extended to 18.7 (1.2) days when transduction was combined with a low dose of rapamycin, a significant improvement over survival with rapamycin treatment alone (13.2 [0.6] days) (P < .01). These results demonstrated that local immunomodulation by the allograft itself and low-dose rapamycin treatment promote graft acceptance. This protocol may enable reduction of the dosage of immunosuppressive drugs needed for successful inhibition of acute rejection in the early postoperative period.lld:pubmed
pubmed-article:21094862pubmed:languageenglld:pubmed
pubmed-article:21094862pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21094862pubmed:citationSubsetIMlld:pubmed
pubmed-article:21094862pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21094862pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21094862pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21094862pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21094862pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21094862pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21094862pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21094862pubmed:statusMEDLINElld:pubmed
pubmed-article:21094862pubmed:monthNovlld:pubmed
pubmed-article:21094862pubmed:issn1873-2623lld:pubmed
pubmed-article:21094862pubmed:authorpubmed-author:YuC CCClld:pubmed
pubmed-article:21094862pubmed:authorpubmed-author:YangYYlld:pubmed
pubmed-article:21094862pubmed:authorpubmed-author:LUMMlld:pubmed
pubmed-article:21094862pubmed:authorpubmed-author:KayE JEJlld:pubmed
pubmed-article:21094862pubmed:authorpubmed-author:XiaoBBlld:pubmed
pubmed-article:21094862pubmed:authorpubmed-author:XieSSlld:pubmed
pubmed-article:21094862pubmed:authorpubmed-author:GOTTlld:pubmed
pubmed-article:21094862pubmed:copyrightInfoCopyright © 2010 Elsevier Inc. All rights reserved.lld:pubmed
pubmed-article:21094862pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21094862pubmed:volume42lld:pubmed
pubmed-article:21094862pubmed:ownerNLMlld:pubmed
pubmed-article:21094862pubmed:authorsCompleteYlld:pubmed
pubmed-article:21094862pubmed:pagination3815-9lld:pubmed
pubmed-article:21094862pubmed:meshHeadingpubmed-meshheading:21094862...lld:pubmed
pubmed-article:21094862pubmed:meshHeadingpubmed-meshheading:21094862...lld:pubmed
pubmed-article:21094862pubmed:meshHeadingpubmed-meshheading:21094862...lld:pubmed
pubmed-article:21094862pubmed:meshHeadingpubmed-meshheading:21094862...lld:pubmed
pubmed-article:21094862pubmed:meshHeadingpubmed-meshheading:21094862...lld:pubmed
pubmed-article:21094862pubmed:meshHeadingpubmed-meshheading:21094862...lld:pubmed
pubmed-article:21094862pubmed:meshHeadingpubmed-meshheading:21094862...lld:pubmed
pubmed-article:21094862pubmed:meshHeadingpubmed-meshheading:21094862...lld:pubmed
pubmed-article:21094862pubmed:meshHeadingpubmed-meshheading:21094862...lld:pubmed
pubmed-article:21094862pubmed:meshHeadingpubmed-meshheading:21094862...lld:pubmed
pubmed-article:21094862pubmed:meshHeadingpubmed-meshheading:21094862...lld:pubmed
pubmed-article:21094862pubmed:meshHeadingpubmed-meshheading:21094862...lld:pubmed
pubmed-article:21094862pubmed:meshHeadingpubmed-meshheading:21094862...lld:pubmed
pubmed-article:21094862pubmed:meshHeadingpubmed-meshheading:21094862...lld:pubmed
pubmed-article:21094862pubmed:meshHeadingpubmed-meshheading:21094862...lld:pubmed
pubmed-article:21094862pubmed:meshHeadingpubmed-meshheading:21094862...lld:pubmed
pubmed-article:21094862pubmed:meshHeadingpubmed-meshheading:21094862...lld:pubmed
pubmed-article:21094862pubmed:meshHeadingpubmed-meshheading:21094862...lld:pubmed
pubmed-article:21094862pubmed:meshHeadingpubmed-meshheading:21094862...lld:pubmed
pubmed-article:21094862pubmed:meshHeadingpubmed-meshheading:21094862...lld:pubmed
pubmed-article:21094862pubmed:meshHeadingpubmed-meshheading:21094862...lld:pubmed
pubmed-article:21094862pubmed:meshHeadingpubmed-meshheading:21094862...lld:pubmed
pubmed-article:21094862pubmed:year2010lld:pubmed
pubmed-article:21094862pubmed:articleTitleUse of genetically modified allograft to deliver local immunomodulatory molecule with minimal systemic toxicity in a rat model of allogeneic skin flap transplantation.lld:pubmed
pubmed-article:21094862pubmed:affiliationInstitute of Plastic Surgery, Xijing Hospital, Fourth Military Medical University, Xi’an, Shanxi Province, China.lld:pubmed
pubmed-article:21094862pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21094862pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed